Compare Charles River Laboratories Intl. Inc (CRL) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 3.6× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| CRL | VCSH | |
|---|---|---|
Market Cap | $14.23B | $51.90B |
Volume | 1,176,885 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $310.77 | $80.20 |
52-Week Low | $149.93 | $77.03 |
Typical Hold Time | 33 Days | 52 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298.00, down 0.77% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of -$144.34M for 2025. Analyst consensus is strongly positive with a $305.50 price target, and recent news highlights a strategic growth plan targeting 5%-7% revenue growth by 2030.
The stock's outlook is supported by strong analyst buy ratings and a clear growth strategy, but faces risks from negative profitability metrics and high valuation multiples. Investment opportunity hinges on successful execution of margin expansion and cost savings initiatives, while key risks include persistent net losses and competitive pressures in the healthcare services sector.
VCSH trades at $77.34, showing minimal daily movement with a 0.09% gain. Technical indicators signal a bearish trend overall, with moving averages suggesting selling pressure while oscillators remain neutral. The ETF maintains consistent $0.30 dividend payments scheduled through October 2026. Recent news coverage highlights VCSH's competitive 0.03% expense ratio and 4.5-4.8% dividend yield compared to peer funds.
VCSH offers exposure to short-term investment-grade corporate bonds with minimal interest rate risk due to its 2.7-year duration. The primary risk involves credit spread compression limiting near-term upside potential. Institutional activity shows mixed signals with both position increases and decreases reported in recent quarters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
